Vorinostat, cladribine and rituximab (SCR) for relapsed lymphoma and mantle cell – pro
A recent a phase II study published as abstract in June fo 2019.In that study, there was vorinostat (SAHA), cladribine and rituximab (SCR) in nonHodgkin lymphomas (NHL), most mntel cell, in this phase 12 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously (IV) (days 15), rituximab 375 mg/m2 IV (weekly 4× for cycle 1 and 1×/month) and vorinostat orally once daily (days 114) every 28 days for up to six cycles. Phase 1 included relapsed patients (n = 10) in a standard 3 + 3 dose escalation design (vorinostat: 200, 300 and 400 mg). No doselimiting toxicities were seen. The phase 2 dose for vorinostat was 400 mg po (days 114). At a median followup of 42 months, median progressionfree survival (PFS) and overall survival (OS) for relapsed NHL were 19·5 [95% confidence interval (CI): 2·033·0] and 25·0 (95% CI: 12·045·0) months respectively. Median PFS for previously untreated MCL was 84·0 months; OS could not be estimated. Toxicities were primarily haematological.
Spurgeon SE et al, Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
Br J Haematol. 2019 Jun 9.
Ogura MA et al, multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Br J Haematol. 2014 Jun;165(6):768-76.
Stephen E. Spurgeon Kamal Sharma David F. Claxton Christopher Ehmann Jeffrey Pu Sara Shimko August Stewart Nan Subbiah Gundula Palmbach Francis LeBlanc Emile Latour YiYi Chen Motomi Mori Zainul Hasanali Elliot M. EpnerPhase 12 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed Bcell nonHodgkin lymphoma and previously untreated mantle cell lymphoma BJH https://onlinelibrary.wiley.com/doi/10.1111/bjh.16008
More studies re needed.